GENET archive

[Index][Thread]

8-Humans: Dolly scientist wins approval to create human embroys



-----------------------
genet-news mailing list
-----------------------

-------------------------------- GENET-news --------------------------------

TITLE:  Human cloning: Dolly scientist wins approval to use 'virgin birth'
        technique
SOURCE: The Independent, UK, by Steve Connor
        http://news.independent.co.uk/world/science_medical/story.jsp?story
        =414102
DATE:   June 10, 2003

------------------ archive: http://www.gene.ch/genet.html ------------------


Human cloning: Dolly scientist wins approval to use 'virgin birth' technique

Bees do it, ants do it, and so apparently did the Goddess Athena.
Parthenogenesis - Greek for "virgin birth" - could now allow British
scientists to create human embryos from unfertilised eggs.

Athena was perhaps the first mythical character to undergo
parthenogenesis, having emerged fully formed from the forehead of her
father, Zeus. Hence her temple on the Acropolis is called The Parthenon.

Yesterday, Britain's fertility watchdog gave approval for scientists to
create human embryos using a parthenogenetic process, in a landmark
experiment that could pave the way for human cloning.

The Human Fertilisation and Embryology Authority (HFEA) granted a licence
to the Roslin Institute, near Edinburgh, to use human eggs and embryos to
generate embryonic stem cells which could be used to produce the
specialised tissues of the body.

Professor Ian Wilmut, the scientist who cloned Dolly the sheep, will lead
the Roslin team in its attempts to "activate" human eggs so that they
develop into early embryos without first being fertilised by sperm cells.

The technique will in effect result in human embryos that cannot develop
into fully mature and viable foetuses. The idea is to bypass many of the
ethical concerns about experimenting with entities that could be
considered potential human beings.

Harry Griffin, the acting director of the institute, said the licence
would also allow the institute to culture immature egg cells from frozen
ovarian tissue to boost the supply of fully mature human eggs.

The Roslin needs a large supply of eggs to carry out cloning by the Dolly
technique, which will require a separate licence. "It helps us overcome a
key limiting factor, which is the shortage of human eggs," Dr Griffin said.

A statement from the HFEA said that any stem cells created under the
licence would be used for research purposes only, such as the possible
testing of new medicines or the study of congenital diseases. Suzi
Leather, who chairs the HFEA, said: "It is important that any research
involving human embryos is scrutinised and properly regulated."

The licence allows the Roslin Institute to carry out research on "spare"
embryos that have been donated by couples undergoing IVF treatment. It
also allows the Roslin to experiment with unfertilised human eggs to
create embryos by parthenogenesis.

Many species of animals, especially insects, use parthenogenesis as a
form of natural reproduction. However, attempts at using artificial
parthenogenesis in mammals have never been able to produce viable
foetuses that developed normally.

Because of this, some American scientists do not even consider mammalian
embryos made by parthenogenesis as embryos, preferring instead to call
them "parthenotes". In 2001, the American biotechnology company Advanced
Cell Technology (ACT) claimed to have produced early human embryos by
parthenogenesis, but the research claims were subsequently criticised.
But last year the same company announced the successful extraction of
stem cells from monkey embryos created by parthenogenesis.

Robert Lanza, a member of the ACT team, said that the Roslin's licence to
conduct similar research on human eggs would help in the understanding of
cloning using the Dolly technique of replacing an egg cell's nucleus with
the nucleus from another cell - so-called cell nuclear replacement.

"In the field of cloning, before you proceed with nuclear transfer of any
species, you need to work out the activation protocol. That is learning
how to fool the egg into thinking it is fertilised," Dr Lanza said.

But Christopher Barratt, professor of reproductive medicine at the
University of Birmingham, dismissed the idea that the licence brought
human therapeutic cloning by cell nuclear replacement closer. "It doesn't
pave the way for cloning just because one aspect of their proposal
involves the artificial activation of eggs so there is no transfer of a
donor nucleus into a human egg," he said.

Professor Barratt, a member of the HFEA, said that the research was
important because it could lead to the generation of human stem cells
that could be used in transplant operations. "There are experiments on
monkeys where parthenogenetic activation of eggs has developed stem cells
and there is some evidence to suggest that these stem cells will develop
into, for example, neurons [nerve cells]," he said.

Three other institutes in Britain have licences to extract stem cells
from human embryos to research the possibility of using them to treat
disorders such as Parkinson's disease, but the Roslin is the first to
have a licence to generate human embryos by parthenogenesis.

In normal sexual reproduction, an egg or sperm loses half of its
chromosomes so that when the two come together during fertilisation the
full number is restored in the resulting embryo. In parthenogenesis, an
unfertilised human egg is tricked into keeping the set of chromosomes
that it would have otherwise lost. The result is an embryo that retains
the full set of maternal DNA.

This year, it was reported that an American biotech company called
Stemron had grown parthenogenetic human embryos. A spokeswoman for the
HFEA said that the Roslin first got its parthenogenesis licence in June
2002, but only after an article in The Independent did the information
became public. The HFEA denied that it was unduly secretive, saying it
had a duty of confidentiality onlicence applications until they were granted.

Although it might be possible to extract stem cells from parthenogenetic
embryos, their usefulness is questionable because they will consist
entirely of maternal DNA. It would also be impossible to use this
technique to generate a man's stem cells. A technique that could overcome
this is cell nuclear replacement - or therapeutic cloning - where empty
eggs cells are filled with a cell nucleus taken from the skin of a man or
woman to generate a true embryonic clone.

The HFEA said it had not yet received a formal application to conduct
that sort of research, but The Independent has learnt that at least one
institute is in the final stages of negotiating criteria to apply for
such a licence.

One scientist close to the authority said: "[Nuclear transfer is] moving
at an incredibly rapid speed and I would envisage a number of
applications for cell nuclear transfer coming along in the next few months."




--


GENET
European NGO Network on Genetic Engineering

Hartmut MEYER (Mr)
Kleine Wiese 6
D - 38116 Braunschweig
Germany

phone:  +49-531-5168746
fax:    +49-531-5168747
mobile: +49-162-1054755
email:  genetnl(at)xs4all.be